Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001386020 | SCV001586100 | pathogenic | Neurofibromatosis, type 1 | 2022-08-09 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. ClinVar contains an entry for this variant (Variation ID: 1073116). Disruption of this splice site has been observed in individual(s) with neurofibromatosis (PMID: 19061981; Invitae). This variant is not present in population databases (gnomAD no frequency). This sequence change affects an acceptor splice site in intron 7 of the NF1 gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in NF1 are known to be pathogenic (PMID: 10712197, 23913538). |
Human Genetics Bochum, |
RCV002463812 | SCV002758571 | pathogenic | Neurofibromatosis-Noonan syndrome | 2022-10-11 | criteria provided, single submitter | clinical testing | ACMG criteria used to clasify this variant: PVS1, PM2, PS4 |
Baylor Genetics | RCV003463010 | SCV004198330 | pathogenic | Juvenile myelomonocytic leukemia | 2024-01-22 | criteria provided, single submitter | clinical testing | |
Laboratory for Genotyping Development, |
RCV003169948 | SCV002758174 | pathogenic | Gastric cancer | 2021-07-01 | no assertion criteria provided | research |